Examkin

Question

Difficulty: HardBias, Confounding, and Validity

Rheumatology researchers are designing a multicenter observational study to evaluate the cardiovascular safety profile of Janus kinase (JAK) inhibitors versus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The primary outcome is the incidence of major adverse cardiovascular events (MACE). During the planning phase, the team notes a critical challenge: physicians intentionally avoid prescribing JAK inhibitors to patients with pre-existing cardiovascular risk factors. Because these same risk factors independently increase the likelihood of developing MACE, this dynamic threatens the internal validity of the study.

To effectively mitigate this threat and isolate the true association between the pharmacological therapies and MACE, which of the following strategies are appropriate to implement? (Select all that apply)

  1. Matching participants in the JAK inhibitor and csDMARD cohorts according to their baseline cardiovascular risk profiles.Answer
  2. Incorporating baseline cardiovascular risk factors as covariates in a multivariable Cox proportional hazards regression model.Answer
  3. C
    Reporting stratum-specific hazard ratios for MACE without calculating a pooled estimate, conceptualizing baseline cardiovascular risk as an effect modifier.
  4. D
    Utilizing an independent-samples t-test to compare the mean time-to-MACE between the two unadjusted pharmacological cohorts.
  5. E
    Weighting the baseline cardiovascular risk factors based on their positive and negative predictive values to adjust the final MACE incidence rates.

Answer

The correct strategies are matching participants according to baseline risk profiles and incorporating risk factors into a multivariable Cox regression model.
The correct answers identify established methods for mitigating confounding in observational studies. Confounding occurs when an extraneous variable is associated with both the exposure and the outcome, distorting the observed relationship. In this scenario, baseline cardiovascular risk is the confounder. Matching patients during the study design phase ensures that the confounder is equally distributed between the treatment and control groups. Alternatively, incorporating the confounder into a multivariable Cox proportional hazards regression model during the analysis phase mathematically adjusts for its influence, allowing researchers to isolate the independent effect of the JAK inhibitors on the time-to-MACE.

Step-by-Step Solution

1
Identify the epidemiological phenomenon described in the scenario.
The scenario describes a variable (baseline cardiovascular risk) that affects both the exposure (likelihood of receiving a JAK inhibitor) and the outcome (MACE).
Recognizing the relationship between these variables defines the phenomenon as confounding, specifically confounding by indication.
2
Determine appropriate methods to control for confounding.
Confounding can be controlled during the design phase (randomization, matching, restriction) or the analysis phase (stratification with pooling, multivariable regression, propensity scoring).
Applying the correct epidemiological tools is required to mitigate the threat to internal validity.
3
Evaluate each provided option against the identified valid methods.
Matching cohorts by risk profile and utilizing a multivariable Cox regression model are valid techniques to control for confounding.
Other options incorrectly treat the confounder as an effect modifier, utilize incorrect statistical tests, or inappropriately apply diagnostic test metrics.

Key Concept

Confounding variables obscure the true relationship between an exposure and an outcome. They must be controlled during study design (via matching or restriction) or data analysis (via multivariable regression or stratification with pooling) to ensure internal validity.
Rate this question

Topics

Bias, Confounding, and Validity

More questions from this topic